Analysts at Cantor Fitzgerald started coverage on shares of Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) in a research report issued on Tuesday, The Fly reports. The brokerage set a “buy” rating on the biopharmaceutical company’s stock.
Separately, Aegis set a $12.00 target price on Corbus Pharmaceuticals Holdings and gave the stock a “buy” rating in a report on Monday, September 19th.
Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) traded up 2.18% during mid-day trading on Tuesday, reaching $7.02. The company’s stock had a trading volume of 530,799 shares. The company’s market capitalization is $307.11 million. Corbus Pharmaceuticals Holdings has a one year low of $1.01 and a one year high of $7.88. The stock has a 50-day moving average price of $5.27 and a 200-day moving average price of $3.30.
Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last posted its earnings results on Monday, August 15th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by $0.03. Corbus Pharmaceuticals Holdings had a negative return on equity of 107.10% and a negative net margin of 890.44%. Equities research analysts forecast that Corbus Pharmaceuticals Holdings will post ($0.40) EPS for the current year.
In other Corbus Pharmaceuticals Holdings news, CFO Sean F. Moran acquired 148,960 shares of the firm’s stock in a transaction dated Thursday, August 18th. The stock was purchased at an average price of $3.32 per share, for a total transaction of $494,547.20. Following the acquisition, the chief financial officer now owns 216,410 shares in the company, valued at approximately $718,481.20. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Sean F. Moran acquired 17,900 shares of the firm’s stock in a transaction dated Friday, August 26th. The shares were acquired at an average price of $3.92 per share, with a total value of $70,168.00. Following the acquisition, the chief financial officer now owns 299,310 shares in the company, valued at approximately $1,173,295.20. The disclosure for this purchase can be found here. Insiders own 11.60% of the company’s stock.
Corbus Pharmaceuticals Holdings Company Profile
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases.
Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.